<DOC>
	<DOCNO>NCT03025867</DOCNO>
	<brief_summary>This expanded access program ( EAP ) eligible patient Recurrent Ovarian Cancer . This program design provide access niraparib prior approval US Food Drug Administration ( FDA ) . To eligible , patient Recurrent Ovarian Cancer follow partial ( PR ) complete response ( CR ) recent platinum-based chemotherapy must experience PR CR penultimate ( next last ) platinum-based chemotherapy least 6 month without disease progression chemotherapy .</brief_summary>
	<brief_title>Expanded Access Protocol Niraparib Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>If patient qualifies participation ongoing niraparib clinical trial already participate niraparib clinical trial , able participate EAP . Ongoing clinical trial niraparib include : - A Phase 3 trial patient receive first-line treatment ovarian cancer ( PRIMA trial , NCT # 02655016 ) - A Phase 2 trial patient receive multiple line treatment ovarian cancer ( QUADRA trial , NCT # 02354586 ) - A Phase 1/2 trial patient advance metastatic triple-negative breast cancer recurrent ovarian cancer . ( TOPACIO trial , NCT # 02657889 )</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>1 . Histologically diagnosed ovarian cancer , fallopian tube cancer , primary peritoneal cancer 2 . Completion least 2 previous course platinumcontaining chemotherapy . 3 . Had CR PR duration response &gt; /=6 month follow penultimate chemotherapy 4 . Achieved partial ( PR ) complete ( CR ) tumor response follow completion last platinumcontaining chemotherapy [ minimum 4 cycle ] 5 . Patients previously treat PARP inhibitor eligible 6 . Eastern Cooperative Oncology Group ( ECOG , http : //ecogacrin.org/ ) performance status 0 1 7 . Adequate organ function [ Absolute neutrophil count ( ANC ) ≥ ( great equal ) 1,500/µL ; Platelets ≥ ( great equal ) 100,000/µL ; Hemoglobin ≥ ( great equal ) 9 g/dL ] 8 . Able take oral medication 9 . Women pregnant begin treatment woman childbearing potential become pregnant niraparib 10 . Patient start treatment niraparib later 12 week completion final dose platinumcontaining chemotherapy 1 . Persistent ≥Grade 2 hematologic toxicity prior cancer therapy 2 . Known hypersensitivity component niraparib 3 . Patient pregnant breast feeding , expect conceive child within project duration program treatment 4 . Patient uncontrolled hypertension</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>